Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jun 20, 2008

PPD Expands Eastern European Presence

  • PPD opened an office in Istanbul, Turkey as part of the planned growth of its  Phase II-IV clinical development services in Eastern Europe. PPD already has offices in Russia and the Ukraine.

    PPD will provide clinical monitoring services in key therapeutic areas from this location.

    "With a population of 74 million people, Turkey is becoming an attractive place to conduct clinical trials," said Fred Eshelman, CEO of PPD. "Eastern Europe offers recruitment opportunities and quality investigators, and our Istanbul office is an important part of our strategic growth in this region."

    Related Links:

    Regulations Still Driving Stability Testing

    Unlocking the Secrets of Protein Profiling



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »